A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
← catalyst calendarSponsored by Ascentage Pharma Group Inc. (industry) · AAPG — their whole pipeline →. With Merck Sharp & Dohme LLC.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
230estimated
Sites
21
Countries
Australia, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2018-08-29 | actual | When the study began enrolling |
| Primary completion | 2025-12-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-12-30 | estimated | The whole study's end, after follow-up |
| First posted | 2018-08-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Unresectable or Metastatic Melanoma or Advanced Solid Tumors
- Melanoma
- Uveal Melanoma
- P53 Mutation
- MDM2 Gene Mutation
- Cutaneous Melanoma
- Mucosal Melanoma
- Malignant Peripheral Nerve Sheath Tumors (MPNST)
Intervention
- Drug: Phase 1b: APG-115+pembrolizumab — also filed as KEYTRUDA®
Primary outcomes
what the primary-completion date above is the date OFMaximum Tolerated Dose
measured 21 days
Recommended Phase II Dose
measured 21 days
Overall Response Rate
measured up to 12 months
Permalink · AAPG's whole pipeline · Catalyst calendar · Every registered study · What changed